Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline.Tevogen Bio created a data set containing known proteins in the HPV genome to identify targets, accelerating the pre-clinical process.5.5 million women per year have HPV 16/18; of these 200,000 women per year are diagnosed with high grade dysplasia. WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunoth ...